BCM
SUPN icon

Bayesian Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bayesian Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,502
Closed -$222K – 1079
2024
Q1 		$222K Buy
+6,502
New +$194K 0.02% 634
2019
Q2 		– Sell
-13,718
Closed -$481K – 673
2019
Q1 		$481K Buy
13,718
+6,841
+99% +$255K 0.09% 298
2018
Q4 		$228K Sell
6,877
-300
-4% -$12.9K 0.05% 482
2018
Q3 		$361K Buy
7,177
+470
+7% +$23.2K 0.06% 406
2018
Q2 		$401K Buy
+6,707
New +$347K 0.09% 323
2016
Q4 		– Sell
-9,500
Closed -$235K – 699
2016
Q3 		$235K Buy
+9,500
New +$215K 0.15% 247

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bayesian Capital Management's SUPN Position: Q2 2024 in Review

Bayesian Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 6,502 shares — an estimated $222K sold.

Bayesian Capital Management first reported a position in SUPN in Q3 2016 and held it in 6 quarters. The position peaked at $481K in Q1 2019. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

  • Bayesian Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 6,502 Supernus Pharmaceuticals shares in Q2 2024, an estimated $222K.
  • Bayesian Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 6 quarters.
  • Bayesian Capital Management's Supernus Pharmaceuticals position peaked at $481K in Q1 2019.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.